Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 16/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13217402 | 0.81 | DPP4 (0.47) | — | |
| SCHEMBL6417245 | 0.79 | DPP4 (0.34) | KAT2BBPTFSPRBTK | |
| SCHEMBL27623279 | 0.74 | HTR3A (0.40) | — | |
| SCHEMBL22464692 | 0.74 | BCHE (0.54) | — | |
| SCHEMBL6408912 | 0.73 | SLC6A9 (0.34) | — | |
| SCHEMBL13217366 | 0.71 | HTR3A (0.44) | TSHRHSD17B10 | |
| SCHEMBL16505439 | 0.71 | PIM2 (0.42) | KAT2BBPTFGAATSHRHSD17B10 | |
| SCHEMBL2572216 | 0.71 | PIM2 (0.42) | KAT2BBPTFGAATSHRHSD17B10 | |
| SCHEMBL16505148 | 0.71 | PIM2 (0.42) | KAT2BBPTFGAATSHRHSD17B10 | |
| SCHEMBL16504578 | 0.68 | MEN1 (0.40) | OPRK1GAABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| CN-100469778-C | Novel fused imidazole derivatives | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | CN | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| CN-100348599-C | Novel fused imidazole derivatives | EISAI CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| CN-1931859-A | New fused imidazole derivative | EISAI CO LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| CN-1700911-A | Combination drug | EISAI CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| CN-1675208-A | Novel fused imidazole derivatives | EISAI CO LTD (JP) | 2005-09-28 | — | — | CN | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1514552-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | Eisai Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | KAT2B 1634/4885BPTF 3095/4885SPR 2865/4885 |
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | KAT2B 648/4885BPTF 1300/4885SPR 4378/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | KAT2B 3476/4885BPTF 1871/4885SPR 1567/4885 |
| US-20060063787-A1 | Condensed imidazole derivatives | DPP4, HDAC1, DPP7 | KAT2B 1271/4885BPTF 1560/4885SPR 2102/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | KAT2B 1271/4885BPTF 1560/4885SPR 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.